Literature DB >> 35396544

Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study.

Jordan Hindson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35396544     DOI： 10.1038/s41575-022-00616-8

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

Authors:  Do-Youn Oh; Kyung-Hun Lee; Dae-Won Lee; Jeesun Yoon; Tae-Yong Kim; Ju-Hee Bang; Ah-Rong Nam; Kyoung-Seok Oh; Jae-Min Kim; Young Lee; Violeta Guthrie; Patricia McCoon; Weimin Li; Song Wu; Qu Zhang; Marlon C Rebelatto; Jin Won Kim
Journal:  Lancet Gastroenterol Hepatol       Date:  2022-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.